U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H15Cl3N2OS.HNO3
Molecular Weight 500.783
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERTACONAZOLE NITRATE

SMILES

O[N+]([O-])=O.ClC1=CC(Cl)=C(C=C1)C(CN2C=CN=C2)OCC3=CSC4=C3C=CC=C4Cl

InChI

InChIKey=HAAITRDZHUANGT-UHFFFAOYSA-N
InChI=1S/C20H15Cl3N2OS.HNO3/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22;2-1(3)4/h1-8,11-12,19H,9-10H2;(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula HNO3
Molecular Weight 63.0128
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H15Cl3N2OS
Molecular Weight 437.77
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/ertaczo-drug.htm https://www.drugs.com/mtm/sertaconazole-topical.html http://www.wikidoc.org/index.php/Sertaconazole

Sertaconazole is a azole antifungal that is FDA approved for the treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Sertaconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Common adverse reactions include contact dermatitis, dry skin, burning skin and application site skin tenderness.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ERTACZO

Approved Use

ERTACZO® (sertaconazole nitrate) Cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (see CLINICAL STUDIES Section).

Launch Date

2003
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.79 ng/mL
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
43.31 ng × h/mL
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.25 h
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
SERTACONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 % 2 times / day steady, topical
Highest studied dose
Dose: 2 %, 2 times / day
Route: topical
Route: steady
Dose: 2 %, 2 times / day
Sources: Page: 6.1
healthy, adult
n = 202
Health Status: healthy
Age Group: adult
Sex: unknown
Population Size: 202
Sources: Page: 6.1
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans.
1992 May
In vitro antifungal activity of sertaconazole.
1992 May
In vitro activity of sertaconazole.
1992 May
In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp.
1995 Oct
Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp.
1996 Mar-Apr
Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes.
1997 Nov-Dec
Patents

Sample Use Guides

Cream should be applied to the affected and immediate surrounding area(s) twice daily for 4 weeks.
Route of Administration: Topical
In Vitro Use Guide
MIC for Candida parapsilosis (0.26 mg/l) demonstrated a higher activity of sertaconazole against this species, in contrast to Candida tropicalis (MIC 1.49 mg/l). Against dermatophytes, MIC for sertaconazole was MIC 0.41 mg/l and against Cryptococcus neoformans yeasts - arithmetic mean MIC 1.24 mg/l.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:32:23 GMT 2023
Edited
by admin
on Fri Dec 15 15:32:23 GMT 2023
Record UNII
1DV05410M5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERTACONAZOLE NITRATE
EP   MART.   MI   ORANGE BOOK   WHO-DD  
Common Name English
SERTACONAZOLE NITRATE [MART.]
Common Name English
DERMOVIT
Brand Name English
SERTACONAZOLE NITRATE [ORANGE BOOK]
Common Name English
SERTACONAZOLE NITRATE [EP MONOGRAPH]
Common Name English
1H-IMIDAZOLE, 1-(2-((7-CHLOROBENZO(B)THIEN-3-YL)METHOXY)-2-(2,4-DICHLOROPHENYL)ETHYL)-, NITRATE (1:1)
Systematic Name English
FI 7056
Code English
ZALAIN
Brand Name English
Sertaconazole nitrate [WHO-DD]
Common Name English
DERMOFIX
Brand Name English
1H-IMIDAZOLE, 1-(2-((7-CHLOROBENZO(B)THIEN-3-YL)METHOXY)-2-(2,4-DICHLOROPHENYL)ETHYL)-, MONONITRATE
Systematic Name English
ERTACZO
Brand Name English
SERTACONAZOLE MONONITRATE
Common Name English
SERTACONAZOLE NITRATE [MI]
Common Name English
FI-7056
Code English
Code System Code Type Description
RXCUI
236601
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY RxNorm
FDA UNII
1DV05410M5
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
DRUG BANK
DBSALT001382
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID2045529
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
NCI_THESAURUS
C47716
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
PUBCHEM
200103
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
EVMPD
SUB04374MIG
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
DAILYMED
1DV05410M5
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
MERCK INDEX
m9874
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY Merck Index
CAS
99592-39-9
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
CHEBI
83687
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
SMS_ID
100000084931
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201196
Created by admin on Fri Dec 15 15:32:24 GMT 2023 , Edited by admin on Fri Dec 15 15:32:24 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY